Resources

Uncovering real-world insights into MDS treatment in Australia: Our study in eJHaem highlights the importance of treatment adherence and the need for innovative solutions.

The study analysed real-world data to compare treatment persistence and adherence among PAH patients on ERAs in Japan. Results showed significantly higher persistence with a medication compared to the other two medications.

This study aimed to examine patient characteristics, persistence and adherence to treatment associated with use of second-generation antipsychotic long-acting injectable (SGA LAI) medications in the Australian real-world setting.

Gout is the most common form of inflammatory arthritis in men. Despite the availability of effective urate-lowering therapies (ULT), the management of gout is suboptimal due to poor persistence with ULT. This study examined national prescribing patterns of ULT to...

This study analysed the utilization of ibrutinib, a BTK inhibitor, in treating chronic lymphocytic leukemia in Australia. It compared real-world data from the Pharmaceutical Benefits Scheme (PBS) to the RESONATE clinical trial, providing insights into ibrutinib use in the general...

This study aimed to examine real-world patterns of antipsychotic use in patients with schizophrenia Australia.

This paper compared persistence between patients prescribed intravitreal aflibercept (IVT-AFL) for neovascular age-related macular degeneration (nAMD) in Australia enrolled on a patient support program (PSP) with that of a sample of patients from the Australian PBS dataset (10% PBS sample);...

This study aimed to describe the persistence of biologic disease modifying anti-rheumatic drugs (bDMARDs) in Australian rheumatoid arthritis (RA) patients.

This paper aimed to describe the persistence of treatment with subcutaneous tumor necrosis factor inhibitors (TNFi) adalimumab, etanercept, and golimumab in immune-mediated rheumatic disease (rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis) by treatment sequence (first-line treatment, second-line or further lines...